Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug aims to help COVID survivors breathe easier

NCT ID NCT04652518

Disease control Sponsor: PureTech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called deupirfenidone (LYT-100) in 185 adults who had breathing problems after a serious COVID-19 infection. Participants took either the drug or a placebo for several weeks to see if it improved their ability to walk. The trial was stopped early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deupirfenidone (LYT-100)
What this could lead to
If it worked, this could point toward a treatment for long-term breathing difficulties after COVID-19.
What could go wrong
The trial was terminated early, so we don't have clear results. It was also a small, early-phase study, so even if completed, success was not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

185 people

The number who actually took part.

Started

Dec 2020

Finished

Jul 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Positive result of a molecular RT-qPCR diagnostic test or SARS-CoV-2 RNA result from a clinical specimen deemed clinically associated with the current episode of illness, warranting hospital admission as per investigator's judgement, or previously hospitalized (central and/or local laboratory COVID-19 test results are accepted from any biological material source) * Hospitalization for COVID-19 respiratory disease and treated with supplemental oxygen (including MV, ECMO or any other means of oxygen administration) in hospital for at least 1 day * COVID-19 pneumonia findings on imaging (chest X-ray or CT Scan) with a minimum of two lung lobes involvement * Able to bear weight and ambulate a minimum of 10 m distance (use of inhaled oxygen permitted) * Shortness of breath ≥ grade 3 on mBDS dyspnea scale and not requiring MV, ECMO, NIV, and/or HFNO (nasal O2 is allowed) for at least 72 hours before screening Key Exclusion Criteria: * Pre-existing chronic respiratory condition(s), obstructive or restrictive, for which the patient is actively taking concomitant medication are excluded. Patients with history of Idiopathic Pulmonary Fibrosis (IPF), lung cancer, pulmonary arterial hypertension, other interstitial lung diseases, severe cardiac insufficiency (grade IV) are excluded irrespective of whether they are actively being medicated for those conditions or not. * Pre-existing co-morbid conditions preventing outcome assessments, e.g., neurological, medical, orthopedic injury/disability, disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed COVID-19 diagnosis * Unstable angina or myocardial infarction in the last month prior to screening * Patients on MV, ECMO, NIV, and/or HFNO within the last 72 hours prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 interstitial lung disease long COVID-19 pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 Post-acute COVID-19 respiratory disease

Contacts and locations

Locations

  • Affinity Health Corp

    Nashville, Tennessee, 37203, United States

  • CETI - Centro de Estudos em Terapias Inovadoras

    Curitiba, Paraná, 80030-110, Brazil

  • Center for Advanced Research and Education

    Gainesville, Georgia, 30501, United States

  • Central Florida Pulmonary Group

    Orlando, Florida, 32803, United States

  • Circuit Clinical/Crystal Run Healthcare LLP

    Middletown, New York, 10941, United States

  • Clinica Central S.A

    Villa Regina, Río Negro Province, 8336, Argentina

  • Coastal Pulmonary and Critical Care

    St. Petersburg, Florida, 33704, United States

  • Frostwood Family Medicine

    Houston, Texas, 77024, United States

  • Fundacion Estudios Clinicos

    Rosario, Santa Fe Province, 2000, Argentina

  • GenHarp Clinical Solutions

    Evergreen Park, Illinois, 60805, United States

  • Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital

    London, SE1 9RT, United Kingdom

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Instituto de Doencas do Torax

    Rio de Janeiro, 21941-913, Brazil

  • Investigaciones en Patologias Respiratorias

    San Miguel de Tucumán, Tucumán Province, 4000, Argentina

  • Medical Center of Limited Liability Company "Harmoniya krasy"

    Kiev, 01135, Ukraine

  • National Institute for Infectious Diseases "Prof. Dr. Matei Balş" (Arensia Eploratory Medicine)

    Bucharest, Romania

  • North Alabama Medical Center

    Florence, Alabama, 35630, United States

  • PMSI Republican Clinical Hospital "T. Mosneaga"

    Chisinau, 2025, Moldova

  • Quirino Memorial Medical Center (QMMC)

    Quezon City, 1109, Philippines

  • Southeastern Research Center

    Winston-Salem, North Carolina, 27103, United States

  • Spitalul Clinic De Pneumoftiziologie "Leon Daniello" Cluj-Napoca

    Cluj-Napoca, 400332, Romania

  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes - Timisoara

    Timișoara, 300310, Romania

  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova

    Craiova, 200515, Romania

  • St George's University Hospitals NHS Foundation Trust - St George's Hospital

    London, SW17 0QT, United Kingdom

  • Tampa General Hospital

    Tampa, Florida, 33606, United States

  • The University of Texas Health Sciences Center at San Antonio

    San Antonio, Texas, 78229, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of Pittsburg Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Southern California - Keck School of Medicine

    Los Angeles, California, 90033, United States

  • University of the Philippines Manila - Philippine General Hospital (PGH)

    Manila, 1000, Philippines

  • Vista Health Research

    Miami, Florida, 33176, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.